Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.88
BMY's Cash-to-Debt is ranked lower than
65% of the 886 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.53 vs. BMY: 0.88 )
Ranked among companies with meaningful Cash-to-Debt only.
BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.95 Max: 3.88
Current: 0.88
0.32
3.88
Equity-to-Asset 0.39
BMY's Equity-to-Asset is ranked lower than
84% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. BMY: 0.39 )
Ranked among companies with meaningful Equity-to-Asset only.
BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.46 Max: 0.64
Current: 0.39
0.33
0.64
Debt-to-Equity 0.60
BMY's Debt-to-Equity is ranked lower than
73% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. BMY: 0.60 )
Ranked among companies with meaningful Debt-to-Equity only.
BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.42 Max: 1.01
Current: 0.6
0.08
1.01
Debt-to-EBITDA 1.31
BMY's Debt-to-EBITDA is ranked higher than
59% of the 522 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. BMY: 1.31 )
Ranked among companies with meaningful Debt-to-EBITDA only.
BMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71  Med: 1.22 Max: 2.57
Current: 1.31
0.71
2.57
Interest Coverage 18.10
BMY's Interest Coverage is ranked lower than
64% of the 683 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 132.39 vs. BMY: 18.10 )
Ranked among companies with meaningful Interest Coverage only.
BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.44  Med: 19.6 Max: 45.77
Current: 18.1
8.44
45.77
Piotroski F-Score: 6
Altman Z-Score: 5.25
Beneish M-Score: -3.30
WACC vs ROIC
8.27%
5.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 16.94
BMY's Operating Margin % is ranked higher than
77% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.96 vs. BMY: 16.94 )
Ranked among companies with meaningful Operating Margin % only.
BMY' s Operating Margin % Range Over the Past 10 Years
Min: 10.45  Med: 22.84 Max: 31.24
Current: 16.94
10.45
31.24
Net Margin % 4.37
BMY's Net Margin % is ranked lower than
54% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.73 vs. BMY: 4.37 )
Ranked among companies with meaningful Net Margin % only.
BMY' s Net Margin % Range Over the Past 10 Years
Min: 4.85  Med: 15.78 Max: 56.42
Current: 4.37
4.85
56.42
ROE % 6.71
BMY's ROE % is ranked higher than
51% of the 857 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.75 vs. BMY: 6.71 )
Ranked among companies with meaningful ROE % only.
BMY' s ROE % Range Over the Past 10 Years
Min: 7.21  Med: 19.06 Max: 78.36
Current: 6.71
7.21
78.36
ROA % 2.75
BMY's ROA % is ranked lower than
52% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.29 vs. BMY: 2.75 )
Ranked among companies with meaningful ROA % only.
BMY' s ROA % Range Over the Past 10 Years
Min: 2.99  Med: 8.44 Max: 35.08
Current: 2.75
2.99
35.08
ROC (Joel Greenblatt) % 102.88
BMY's ROC (Joel Greenblatt) % is ranked higher than
96% of the 869 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.64 vs. BMY: 102.88 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.19  Med: 94.31 Max: 155.17
Current: 102.88
51.19
155.17
3-Year Revenue Growth Rate 9.80
BMY's 3-Year Revenue Growth Rate is ranked higher than
65% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. BMY: 9.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 9.8
-8.4
11.8
3-Year EBITDA Growth Rate 26.50
BMY's 3-Year EBITDA Growth Rate is ranked higher than
78% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.90 vs. BMY: 26.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.8 Max: 26.5
Current: 26.5
-26
26.5
3-Year EPS without NRI Growth Rate -20.20
BMY's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 657 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.20 vs. BMY: -20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.4 Max: 30.7
Current: -20.2
-22.9
30.7
GuruFocus has detected 2 Warning Signs with Bristol-Myers Squibb Company BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BMY's 30-Y Financials

Financials (Next Earnings Date: 2018-07-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2017

BMY Guru Trades in Q2 2017

Louis Moore Bacon 110,820 sh (New)
Caxton Associates 6,600 sh (New)
Joel Greenblatt 87,459 sh (+769.29%)
Paul Tudor Jones 82,386 sh (+279.64%)
PRIMECAP Management 6,315,000 sh (+256.20%)
Jim Simons 13,488,200 sh (+108.54%)
Ray Dalio 131,064 sh (+35.58%)
Vanguard Health Care Fund 53,643,117 sh (+1.61%)
Dodge & Cox 29,579,461 sh (+1.58%)
Murray Stahl 48,990 sh (+0.79%)
Tom Gayner 10,000 sh (unchged)
Steven Cohen 200,000 sh (unchged)
Steven Cohen 500,000 sh (unchged)
Jana Partners Sold Out
Ronald Muhlenkamp 177,974 sh (-0.13%)
Mairs and Power 343,043 sh (-0.36%)
First Eagle Investment 11,329 sh (-1.73%)
Frank Sands 16,774 sh (-2.04%)
T Rowe Price Equity Income Fund 3,670,300 sh (-2.13%)
Mario Gabelli 466,082 sh (-9.15%)
Jeff Auxier 6,393 sh (-13.53%)
Ken Fisher 507,027 sh (-23.90%)
Pioneer Investments 80,594 sh (-25.62%)
Kahn Brothers 19,583 sh (-31.49%)
Steven Cohen 100,000 sh (-34.43%)
Manning & Napier Advisors, Inc 2,034,602 sh (-37.14%)
Eaton Vance Worldwide Health Sciences Fund 645,201 sh (-10.57%)
» More
Q3 2017

BMY Guru Trades in Q3 2017

Pioneer Investments 1,338,444 sh (+1560.72%)
First Eagle Investment 49,229 sh (+334.54%)
Paul Tudor Jones 124,964 sh (+51.68%)
Joel Greenblatt 121,594 sh (+39.03%)
Louis Moore Bacon 142,025 sh (+28.16%)
Frank Sands 17,324 sh (+3.28%)
PRIMECAP Management 6,374,900 sh (+0.95%)
Mario Gabelli 467,867 sh (+0.38%)
Murray Stahl 49,015 sh (+0.05%)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Ray Dalio Sold Out
Caxton Associates Sold Out
Ronald Muhlenkamp 177,169 sh (-0.45%)
Ken Fisher 504,493 sh (-0.50%)
Mairs and Power 339,845 sh (-0.93%)
Dodge & Cox 29,054,961 sh (-1.77%)
Kahn Brothers 19,050 sh (-2.72%)
Vanguard Health Care Fund 50,693,892 sh (-5.50%)
Manning & Napier Advisors, Inc 1,884,716 sh (-7.37%)
T Rowe Price Equity Income Fund 3,165,000 sh (-13.77%)
Jim Simons 10,846,600 sh (-19.58%)
Steven Cohen 75,000 sh (-25.00%)
Signature Select Canadian Fund 71,350 sh (-39.92%)
Eaton Vance Worldwide Health Sciences Fund 597,663 sh (-7.37%)
» More
Q4 2017

BMY Guru Trades in Q4 2017

Jeremy Grantham 10,700 sh (New)
Pioneer Investments 2,797,167 sh (+108.99%)
Steven Cohen 115,000 sh (+53.33%)
Louis Moore Bacon 192,140 sh (+35.29%)
Jim Simons 14,302,900 sh (+31.87%)
Joel Greenblatt 154,793 sh (+27.30%)
Ken Fisher 582,213 sh (+15.41%)
PRIMECAP Management 6,557,578 sh (+2.87%)
Dodge & Cox 29,106,111 sh (+0.18%)
Kahn Brothers 19,050 sh (unchged)
First Eagle Investment 49,229 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Frank Sands Sold Out
Murray Stahl 48,915 sh (-0.20%)
Ronald Muhlenkamp 174,575 sh (-1.46%)
Mairs and Power 332,592 sh (-2.13%)
T Rowe Price Equity Income Fund 3,040,000 sh (-3.95%)
Vanguard Health Care Fund 48,534,812 sh (-4.26%)
Mario Gabelli 408,602 sh (-12.67%)
Paul Tudor Jones 29,786 sh (-76.16%)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (-5.33%)
» More
Q1 2018

BMY Guru Trades in Q1 2018

John Hussman 25,000 sh (New)
Leon Cooperman 468,000 sh (New)
Caxton Associates 4,572 sh (New)
PRIMECAP Management 16,430,950 sh (+150.56%)
Paul Tudor Jones 68,575 sh (+130.23%)
Jeff Auxier 7,393 sh (+15.64%)
Mario Gabelli 466,179 sh (+14.09%)
Kahn Brothers 19,750 sh (+3.67%)
Ronald Muhlenkamp 178,436 sh (+2.21%)
Jim Simons 14,528,300 sh (+1.58%)
Tom Gayner 10,000 sh (unchged)
Jeremy Grantham 10,700 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (unchged)
First Eagle Investment Sold Out
Ken Fisher 577,081 sh (-0.88%)
Pioneer Investments 2,742,824 sh (-1.94%)
Murray Stahl 47,115 sh (-3.68%)
Vanguard Health Care Fund 46,688,361 sh (-3.80%)
Dodge & Cox 27,817,611 sh (-4.43%)
Louis Moore Bacon 178,083 sh (-7.32%)
T Rowe Price Equity Income Fund 2,770,000 sh (-8.88%)
Mairs and Power 291,902 sh (-12.23%)
Steven Cohen 75,000 sh (-34.78%)
Joel Greenblatt 23,077 sh (-85.09%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2018-03-31 Reduce -3.80%0.25%$59.92 - $68.98 $ 52.71-18%46,688,361
Dodge & Cox 2018-03-31 Reduce -4.43%0.06%$59.92 - $68.98 $ 52.71-18%27,817,611
T Rowe Price Equity Income Fund 2018-03-31 Reduce -8.88%0.08%$59.92 - $68.98 $ 52.71-18%2,770,000
Ken Fisher 2018-03-31 Reduce -0.88%$59.92 - $68.98 $ 52.71-18%577,081
Leon Cooperman 2018-03-31 New Buy1.11%$59.92 - $68.98 $ 52.71-18%468,000
Mario Gabelli 2018-03-31 Add 14.09%0.02%$59.92 - $68.98 $ 52.71-18%466,179
Ronald Muhlenkamp 2018-03-31 Add 2.21%0.09%$59.92 - $68.98 $ 52.71-18%178,436
Joel Greenblatt 2018-03-31 Reduce -85.09%0.12%$59.92 - $68.98 $ 52.71-18%23,077
Kahn Brothers 2018-03-31 Add 3.67%0.01%$59.92 - $68.98 $ 52.71-18%19,750
First Eagle Investment 2018-03-31 Sold Out 0.01%$59.92 - $68.98 $ 52.71-18%0
Vanguard Health Care Fund 2017-12-31 Reduce -4.26%0.3%$59.94 - $65.35 $ 52.71-16%48,534,812
Dodge & Cox 2017-12-31 Add 0.18%$59.94 - $65.35 $ 52.71-16%29,106,111
T Rowe Price Equity Income Fund 2017-12-31 Reduce -3.95%0.04%$59.94 - $65.35 $ 52.71-16%3,040,000
Ken Fisher 2017-12-31 Add 15.41%0.01%$59.94 - $65.35 $ 52.71-16%582,213
Mario Gabelli 2017-12-31 Reduce -12.67%0.02%$59.94 - $65.35 $ 52.71-16%408,602
Ronald Muhlenkamp 2017-12-31 Reduce -1.46%0.05%$59.94 - $65.35 $ 52.71-16%174,575
Joel Greenblatt 2017-12-31 Add 27.30%0.03%$59.94 - $65.35 $ 52.71-16%154,793
Vanguard Health Care Fund 2017-09-30 Reduce -5.50%0.35%$54.24 - $63.74 $ 52.71-10%50,693,892
Dodge & Cox 2017-09-30 Reduce -1.77%0.02%$54.24 - $63.74 $ 52.71-10%29,054,961
T Rowe Price Equity Income Fund 2017-09-30 Reduce -13.77%0.13%$54.24 - $63.74 $ 52.71-10%3,165,000
Ken Fisher 2017-09-30 Reduce -0.50%$54.24 - $63.74 $ 52.71-10%504,493
Mario Gabelli 2017-09-30 Add 0.38%$54.24 - $63.74 $ 52.71-10%467,867
Ronald Muhlenkamp 2017-09-30 Reduce -0.45%0.01%$54.24 - $63.74 $ 52.71-10%177,169
Joel Greenblatt 2017-09-30 Add 39.03%0.03%$54.24 - $63.74 $ 52.71-10%121,594
First Eagle Investment 2017-09-30 Add 334.54%0.01%$54.24 - $63.74 $ 52.71-10%49,229
Kahn Brothers 2017-09-30 Reduce -2.72%$54.24 - $63.74 $ 52.71-10%19,050
Vanguard Health Care Fund 2017-06-30 Add 1.61%0.1%$51.66 - $57.33 $ 52.71-3%53,643,117
Dodge & Cox 2017-06-30 Add 1.58%0.02%$51.66 - $57.33 $ 52.71-3%29,579,461
T Rowe Price Equity Income Fund 2017-06-30 Reduce -2.13%0.02%$51.66 - $57.33 $ 52.71-3%3,670,300
Ken Fisher 2017-06-30 Reduce -23.90%0.01%$51.66 - $57.33 $ 52.71-3%507,027
Mario Gabelli 2017-06-30 Reduce -9.15%0.02%$51.66 - $57.33 $ 52.71-3%466,082
Ronald Muhlenkamp 2017-06-30 Reduce -0.13%$51.66 - $57.33 $ 52.71-3%177,974
Joel Greenblatt 2017-06-30 Add 769.29%0.06%$51.66 - $57.33 $ 52.71-3%87,459
Kahn Brothers 2017-06-30 Reduce -31.49%0.09%$51.66 - $57.33 $ 52.71-3%19,583
First Eagle Investment 2017-06-30 Reduce -1.73%$51.66 - $57.33 $ 52.71-3%11,329
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP.PFD882.650.23$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:LLY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, NYSE:ABBV, TSE:4151, TSE:4528, NYSE:MRK, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Guru Investment Theses on Bristol-Myers Squibb Company

Baron Funds' Fifth Avenue Growth Fund Comments on Bristol-Myers Squibb Company - Feb 13, 2017

Bristol-Myers Squibb Company (NYSE:BMY) is a leading developer in Immuno-Oncology, the new wave of therapeutics aimed at displacing chemotherapeutics in cancer care with both improved efficacy (measured via survival outcomes) and safety profiles. While the class as a whole represents a success for society, the race for class dominance is heated and has proven to be difficult to predict. Coming into mid-2016, Bristol was the clear leader. The company squandered this lead in July when a widely anticipated clinical trial whose outcome was expected to read out positively, failed. While few question the drug’s efficacy, statistics and poor clinical trial design submarined Bristol and allowed competitor Merck to take the pole position commercially. Given the dire need for this patient population, the FDA granted Merck a pathway to market by the first half of this year that will give Merck at least a one year commercial advantage in time to market versus its competition. As a result, we decided to exit our investment in Bristol. While Merck has become the consensus leader, we think that their combination employs the wrong science approach and that Bristol is one of two players (AstraZeneca, the other) that will have an opportunity to ultimately come out on top given its strategy of combining two immune-therapeutics. We intend to follow the situation closely while looking for a more appropriate time to potentially get back into the investment.



From Baron Funds' Fifth Avenue Growth Fund fourth quarter 2016 commentary.



Check out Ron Baron latest stock trades

Dodge & Cox Comments on Bristol-Myers Squibb - Feb 01, 2017

Once a diversified pharmaceutical company facing significant patent expirations (a “cliff”), Bristol-Myers (NYSE:BMY) has transitioned into a focused biopharmaceutical company that is positioned to grow. Many of its competitors responded to their patent cliffs by expanding into other non-drug areas; Bristol-Myers shed its interests in those assets unrelated to the drug business (e.g., medical supply, nutritionals), focused on specialty drugs, and concentrated on only those therapeutic areas that it believed could be profitable over the long term. Its medicines help millions of people fight against such diseases as cancer, cardiovascular disease, hepatitis, HIV/ AIDS, and rheumatoid arthritis.



In 2016, one of Bristol-Myers’ lead immuno-oncology trials (CheckMate-026) failed and its stock price declined significantly. We think this is a short-term setback, and believe the company’s immuno-oncology business is particularly attractive with its strong pipeline of other drugs, significant growth potential, and reasonable valuation at 20 times forward earnings. After weighing the risks versus the long-term opportunities, we initiated a position in Bristol-Myers, which accounted for 1.3% of the Fund on December 31.





From Dodge & Cox's Stock Fund 2016 shareholder letter.



Check out Dodge & Cox latest stock trades

Baron Funds Comments on Bristol-Myers Squibb Co. - Oct 25, 2016

Bristol-Myers Squibb Company (NYSE:BMY) is a large diversified pharmaceutical company that is one of the leaders in the development of immune-system-stimulating therapies to fight cancer. These efforts are spearheaded by its product Opdivo, now approved to treat several types of cancer. After positive data was released on a rival drug to treat first-line advanced non-small-cell lung cancer, Bristol-Myers revealed that Opdivo did not meet the primary endpoint in a Phase III trial in the same indication, and its shares fell. We have exited our Bristol-Myers position, but are continuing to research the budding immuno-oncology space carefully. (Josh Riegelhaupt)







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Bristol-Myers Squibb - May 23, 2016

After watching and following Bristol-Myers Squibb (NYSE:BMY) for the better part of the last three years we used the weakness in the stock created by the sell-off in the biotech sector to finally initiate a small to medium size position. Bristol specializes in small molecule drugs known as biologics, which are harder for the generic drug companies to replicate, and we are particularly excited about its lead immuno-oncology asset, Opdivo which has shown incredible promise in the treatment of lung cancer, while growing 10-20% month over month since its approval in 2015. Based on our belief in the effectiveness of the PD-1 class drugs, we think there is a high likelihood that Bristol will be able to gain approvals and expand the usage of Opdivo in other types of cancers (melanoma, renal, head and neck, hodgkin’s lymphoma, etc.) and could potentially change the paradigm of cancer’s treatment worldwide.



From Baron Fifth Avenue Growth Fund first quarter commentary 2016.



Check out Ron Baron latest stock trades

Top Ranked Articles about Bristol-Myers Squibb Company

Vanguard Health Care Reduces Abbott, Bristol-Myers Positions Fund's largest sales of the 1st quarter
The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks in the first quarter. Read more...
What Does Earnings Season Volatility Mean for American Airlines, Bristol-Myers Squibb, Chipotle Mexican Grill, MGM, and Universal Health Services?
Advantagene Announces Clinical Trial Collaboration
Bristol-Myers Squibb Stock Shareholder Alert - Kehoe Law Firm, P.C. Investigating
The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY)
BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018
Lifshitz & Miller LLP Announces Investigation of Bristol-Myers Squibb Company, Freshpet, Inc., Geothermal, Inc., Henry Schein, Inc., Ply Gem Holdings, Inc., United American Bank and Xunlei Limited
GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights
Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading Institutional Investors
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline - BMY

Ratios

vs
industry
vs
history
PE Ratio 92.47
BMY's PE Ratio is ranked lower than
92% of the 584 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. BMY: 92.47 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 24.19 Max: 119.16
Current: 92.47
4.09
119.16
Forward PE Ratio 15.50
BMY's Forward PE Ratio is ranked lower than
53% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.00 vs. BMY: 15.50 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 92.47
BMY's PE Ratio without NRI is ranked lower than
92% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.44 vs. BMY: 92.47 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 24.5 Max: 119.16
Current: 92.47
12.33
119.16
Price-to-Owner-Earnings 22.05
BMY's Price-to-Owner-Earnings is ranked higher than
61% of the 320 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.72 vs. BMY: 22.05 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 23.8 Max: 413.04
Current: 22.05
3.57
413.04
PB Ratio 6.74
BMY's PB Ratio is ranked lower than
86% of the 843 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. BMY: 6.74 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.05 Max: 9.54
Current: 6.74
2.46
9.54
PS Ratio 4.12
BMY's PS Ratio is ranked lower than
66% of the 784 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.25 vs. BMY: 4.12 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 3.52 Max: 7.25
Current: 4.12
1.62
7.25
Price-to-Free-Cash-Flow 18.91
BMY's Price-to-Free-Cash-Flow is ranked lower than
51% of the 216 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.03 vs. BMY: 18.91 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.41  Med: 19.86 Max: 375.94
Current: 18.91
7.41
375.94
Price-to-Operating-Cash-Flow 15.52
BMY's Price-to-Operating-Cash-Flow is ranked lower than
56% of the 289 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.21 vs. BMY: 15.52 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.93  Med: 14.69 Max: 97.02
Current: 15.52
6.93
97.02
EV-to-EBIT 16.93
BMY's EV-to-EBIT is ranked lower than
54% of the 599 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.78 vs. BMY: 16.93 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 16.5 Max: 126.7
Current: 16.93
6.2
126.7
EV-to-EBITDA 14.80
BMY's EV-to-EBITDA is ranked lower than
56% of the 623 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.59 vs. BMY: 14.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 14.2 Max: 57.3
Current: 14.8
5.5
57.3
EV-to-Revenue 4.14
BMY's EV-to-Revenue is ranked lower than
66% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.38 vs. BMY: 4.14 )
Ranked among companies with meaningful EV-to-Revenue only.
BMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 3.7 Max: 7.4
Current: 4.14
1.6
7.4
PEG Ratio 6.42
BMY's PEG Ratio is ranked lower than
88% of the 318 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.00 vs. BMY: 6.42 )
Ranked among companies with meaningful PEG Ratio only.
BMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.44 Max: 19.11
Current: 6.42
0.62
19.11
Shiller PE Ratio 23.22
BMY's Shiller PE Ratio is ranked higher than
60% of the 230 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.11 vs. BMY: 23.22 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.76  Med: 18.35 Max: 36.54
Current: 23.22
10.76
36.54
Current Ratio 1.52
BMY's Current Ratio is ranked lower than
73% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. BMY: 1.52 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.65 Max: 2.32
Current: 1.52
1.13
2.32
Quick Ratio 1.39
BMY's Quick Ratio is ranked lower than
64% of the 772 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.02 vs. BMY: 1.39 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.4 Max: 2.06
Current: 1.39
0.93
2.06
Days Inventory 71.37
BMY's Days Inventory is ranked higher than
67% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 116.78 vs. BMY: 71.37 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 72.42  Med: 116.62 Max: 141.93
Current: 71.37
72.42
141.93
Days Sales Outstanding 75.88
BMY's Days Sales Outstanding is ranked lower than
52% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.10 vs. BMY: 75.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 48.27 Max: 76.37
Current: 75.88
35.38
76.37
Days Payable 98.52
BMY's Days Payable is ranked higher than
78% of the 640 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 73.92 vs. BMY: 98.52 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 105.39  Med: 141.65 Max: 230.86
Current: 98.52
105.39
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.00
BMY's Dividend Yield % is ranked higher than
68% of the 725 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. BMY: 3.00 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.75 Max: 7.07
Current: 3
1.99
7.07
Dividend Payout Ratio 2.77
BMY's Dividend Payout Ratio is ranked lower than
98% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.31 vs. BMY: 2.77 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 2.57
Current: 2.77
0.58
2.57
3-Year Dividend Growth Rate 2.70
BMY's 3-Year Dividend Growth Rate is ranked lower than
60% of the 310 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. BMY: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 12.3
Current: 2.7
0
12.3
Forward Dividend Yield % 3.04
BMY's Forward Dividend Yield % is ranked higher than
65% of the 698 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. BMY: 3.04 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.44
BMY's 5-Year Yield-on-Cost % is ranked higher than
63% of the 889 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.94 vs. BMY: 3.44 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 4.31 Max: 8.12
Current: 3.44
2.28
8.12
3-Year Average Share Buyback Ratio 0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 540 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.80 vs. BMY: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: 0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.90
BMY's Price-to-Tangible-Book is ranked lower than
95% of the 774 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.80 vs. BMY: 17.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.16  Med: 12.16 Max: 53.46
Current: 17.9
4.16
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.02
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
52% of the 312 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.58 vs. BMY: 2.02 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.84 Max: 4.08
Current: 2.02
0.97
4.08
Price-to-Median-PS-Value 1.17
BMY's Price-to-Median-PS-Value is ranked lower than
75% of the 692 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.08 vs. BMY: 1.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.55  Med: 0.85 Max: 2.44
Current: 1.17
0.55
2.44
Price-to-Peter-Lynch-Fair-Value 4.02
BMY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
92% of the 188 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.50 vs. BMY: 4.02 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.66  Med: 2.35 Max: 45.77
Current: 4.02
0.66
45.77
Price-to-Graham-Number 8.58
BMY's Price-to-Graham-Number is ranked lower than
96% of the 425 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. BMY: 8.58 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 3.13 Max: 15.06
Current: 8.58
1.53
15.06
Earnings Yield (Greenblatt) % 5.91
BMY's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 888 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.96 vs. BMY: 5.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.1 Max: 16.1
Current: 5.91
0.8
16.1
Forward Rate of Return (Yacktman) % 23.02
BMY's Forward Rate of Return (Yacktman) % is ranked higher than
94% of the 414 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.53 vs. BMY: 23.02 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 2.55 Max: 25.8
Current: 23.02
-15
25.8

More Statistics

Revenue (TTM) (Mil) $21,040.00
EPS (TTM) $ 0.57
Beta0.96
Volatility22.68%
52-Week Range $49.96 - 70.05
Shares Outstanding (Mil)1,634.54

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 21,953 23,154 23,538
EBIT (Mil $) 5,895 6,361 6,181
EBITDA (Mil $) 6,575 7,081 7,091
EPS ($) 3.40 3.76 4.03
EPS without NRI ($) 3.40 3.76 4.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.90%
Dividends per Share ($) 1.65 1.71 1.67

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}